Briefly, the treatment of BRAFV600E-mutated thyroid cancer cells with PLX4032 causes a feedback activation of MAPK/ERK and PI3K/AKT signaling through enhancing HER3 transcription, leading to resistance to PLX4032. The gene discussed is AKT1; the disease is thyroid cancer.